Drug Targeting and Delivery Systems for Breast Cancer Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 361

Special Issue Editors


E-Mail Website
Guest Editor
Department of Experimental Medicine, Systems Biology Group Lab, Sapienza University of Rome, Via A. Scarpa 16, 00163 Rome, Italy
Interests: inositol in endocrine control and carcinogenesis; tumor reversion through epigenetic and microenvironment modification; biophysical control of morphogenesis and differentiation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France
Interests: tumor microenvironment; biomarkers discovery; nanoparticles; organoids; drug screening

Special Issue Information

Dear Colleagues,

Breast cancer is one of the most common tumors in women, and is also one of the leading causes of death. The pathogenesis recognizes a multifactorial pattern, and thus acts differently during the specific stages through which cancer progresses: local development, lymph node metastasis, and the spread over tissues and distal organs (bones, lungs, lenses, and brain). Early diagnosis is critical, since an aggressive neoplastic form is observed in 10-15% of patients, triggering metastasis development within 3 or 10 years.

From a clinical point of view, breast cancer is a fibrotic tumor that is strongly influenced, in terms of its growth and therapeutic response, by interactions with highly heterogenic stromal cell subsets and extracellular matrix components. On the other hand, recent advances in cellular and molecular profiling have dramatically increased our knowledge of cancer biology and opened up a variety of novel approaches that may defeat heterogeneous diseases in precision medicine. Breast cancer heterogeneity implies the need for personalized therapeutic approaches in order to fully characterize and investigate its pathogenetic profile; this is so that novel diagnostic tools, targeted therapies, and drug delivery systems can be developed.

The scope of this Special Issue is to provide knowledge on recent advances through a series of high-quality, multidisciplinary research articles that describe all aspects of new therapeutic strategies in the field of breast cancer treatment. Potential topics include, but are not limited to, the following: the characterization of the tumor microenvironment, targeting of novel biomarkers or cell subsets, drug repurposing, the basis of therapeutic resistance, target therapy, and drug delivery systems for breast cancer treatment. We welcome original research and review articles.

Dr. Mariano Bizzarri
Dr. Mirko Minini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • breast cancer
  • target therapy
  • nanoparticles
  • liposomes
  • microfluidics
  • organoids

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop